How Much Does MOTS-c Really Cost? The Honest Breakdown
Quick Answer
Direct answer: pricing for MOTS-c varies widely because it is not sold through licensed US pharmacies. Insurance coverage and manufacturer programs change the picture significantly.
MOTS-c at a glance:
- Drug class: Mitochondrial-derived peptide
- Route: subcutaneous injection in research
- Typical frequency: varies
- Half-life: minutes systemically
Let's get specific about MOTS-c pricing in 2026. Cash pricing depends on source and varies widely. What you actually pay depends on insurance status, manufacturer programs, and whether you use a discount card.
MOTS-c Cash Price
MOTS-c is not consistently available through licensed US pharmacies, so a "list price" is hard to pin down. Compounded or grey-market pricing varies dramatically.
That number is the starting point — what you actually pay depends on:
- Insurance status (commercial, Medicare, Medicaid, uninsured)
- Manufacturer savings programs (where applicable)
- Discount cards (GoodRx, Cost Plus Drug, manufacturer cards)
- Telehealth bundling (some platforms include the drug in a flat monthly fee)
- Pharmacy choice (chain vs independent vs mail-order)
Insurance Coverage
Coverage for MOTS-c depends on the specific plan and the indication being treated. For FDA-approved indications, prior authorization is the most common gate. For off-label use, coverage is generally not available.
The pattern across the GLP-1 / metabolic medication space is: coverage for diabetes is widespread, coverage for weight loss is improving but still inconsistent, and coverage for any off-label use is rare.
Manufacturer Programs
MOTS-c doesn't have an FDA-approved manufacturer in the US, so traditional savings programs don't apply.
Cash-Pay and Direct-from-Manufacturer Options
Several manufacturers have introduced direct-to-consumer cash channels for their GLP-1 products in response to coverage gaps. These can lower the cash price meaningfully — see our guide to getting GLP-1 medications for current options.
Total Cost Over a Year
A monthly price of $1,000-$1,500 translates to roughly $10,800-$18,000 per year out of pocket without insurance. That's a real number to plan around — many programs that look attractive at $200/month for the first three months reset to full price after the introductory window.
For weight management, the relevant question is whether to plan around long-term use; for this compound, the duration question depends on the indication.
Sponsored — Affiliate Disclosure
Ready to Start Your GLP-1 Journey?
Comparing to Alternatives
Approved insulin-sensitizing therapies include metformin and pioglitazone. Some of those alternatives may be cheaper, covered when MOTS-c isn't, or just better-suited for a particular case. See our cost comparison pages: linked above.
Bottom Line
Don't take the first quoted price as final. Pharmacy choice, savings programs, and direct-pay channels can move the number significantly.
Frequently Asked Questions
Frequently Asked Questions
Related Reading
- What Is MOTS-c? Everything You Should Know Before Starting
- What Nobody Tells You About MOTS-c Side Effects
- MOTS-c Outcomes Decoded: Who Responds Best and Why
- MOTS-c Cycle and Protocol: What Researchers Actually Use
- NAD+ 101: A Plain-English Guide for 2026
- NAD+ Side Effects Decoded: What's Normal vs. What Isn't
Sources
- Birk AV et al. The Mitochondrial-Targeted Peptide SS-31 Selectively Improves Mitochondrial Function. JASN 2013;24:1250.
- Lee C et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis. Cell Metabolism 2015;21:443.
Pricing changes frequently. The numbers on this page reflect publicly available information as of 2026-04-29 and should be verified at the point of purchase.
Related Articles
- →What Is MOTS-c? Everything You Should Know Before Starting
- →What Nobody Tells You About MOTS-c Side Effects
- →MOTS-c Outcomes Decoded: Who Responds Best and Why
- →MOTS-c Cycle and Protocol: What Researchers Actually Use
- →NAD+ 101: A Plain-English Guide for 2026
- →NAD+ Side Effects Decoded: What's Normal vs. What Isn't
